Axolabs GmbH

Biotechnology

  • Short facts

    • Research & Development
  • Year founded 2000
  • 59 Employees (site)
  • Turnover: 5m - <10m EUR

Products/services: Technology Besides other RNA-based approaches, Roche Kulmbach GmbH is currently focused on therapeutics based on the principle of RNA Interference (RNAi). RNAi is a recently discovered natural and catalytic mechanism for selectively silencing genes encoding proteins that play harmful roles in disease. RNAi is triggered by siRNAs, which are short double-stranded RNA molecules. A sequence-specific target mRNA-recognition by the siRNA leads to the cleavage and subsequent degradation of the mRNA and thus prevents the production of the encoded protein. siRNAs have the potential to become a whole new class of innovative therapeutics. In principle, by using RNAi it is possible to silence any given gene in the genome, including as yet "undruggable" target genes. Products Roche Kulmbach GmbH is currently focused on the discovery of novel RNA therapeutics for the treatment of oncological, respiratory and metabolic diseases. Technology Besides other RNA-based approaches, Roche Kulmbach GmbH is currently focused on therapeutics based on the principle of RNA Interference (RNAi). RNAi is a recently discovered natural and catalytic mechanism for selectively silencing genes encoding proteins that play harmful roles in disease. RNAi is triggered by siRNAs, which are short double-stranded RNA molecules. A sequence-specific target mRNA-recognition by the siRNA leads to the cleavage and subsequent degradation of the mRNA and thus prevents the production of the encoded protein. siRNAs have the potential to become a whole new class of innovative therapeutics. In… read more 

Basic data

Company

Axolabs GmbH

Street

Fritz-Hornschuch-Str. 9

PC / City

95326 Kulmbach

County

Upper Franconia

Phone

+49 9221 82762-0

Fax

+49 9221 82762-99

Language skills

English, German

Contact person

Management: Dr. Roland Kreutzer (Mr.)
Management: Dipl. Kfm. Andreas Bossko (Mr.)

Profile/competences

Core competencies

Roche Kulmbach GmbH is Roche's Center of Excellence for the discovery and development of new therapeutics on the basis of ribonucleic acids (RNA). Currently, Roche Kulmbach GmbH focuses on a new class of therapeutics based on the principle of RNA interference (RNAi). RNAi is a natural process to selectively silence endogenous genes and is mediated by small interfering RNAs (siRNAs). Roche Kulmbach GmbH uses synthetic siRNAs to specifically silence disease-associated genes. This universal approach is applied to develop novel therapeutics for the treatment of oncological, respiratory and metabolic diseases.

Roche Kulmbach GmbH was the first company worldwide to focus on the therapeutic potential of RNA interference. Scientists at Roche Kulmbach AG have excellent know-how about the discovery and development of RNAi therapeutics, propelled by the experience gained from 2003-2007 when they were part of the Alnylam Pharmaceuticals organization, a world-leading company in RNAi.

Key sectors / sub-sectors

  • Biotechnology: Technical services for biotechnology
  • Biotechnology: Therapeutic drug development

NACE industries

  • Research and experimental development on biotechnology 72.11

Certifications / awards

not available

Sales markets - target industries

not available

Sales markets - target countries

not available

Cooperation offers

not available